FTC Cracks Down on Illegal Patent Tactics by Drug Companies
Originally Published 2 years ago — by The New York Times
The Federal Trade Commission (FTC) has issued a policy statement warning pharmaceutical companies about a patenting strategy that may be illegal and has contributed to high prices for inhalers. The strategy involves listing patents on inhalers in the federal registry known as the Orange Book, even if they are not directly related to the medication being delivered. This tactic deters generic competition and delays the availability of lower-priced alternatives. The FTC intends to scrutinize companies engaging in this practice, which could help accelerate the availability of affordable generic inhalers in the future.